Stuart Lutzker - 25 Jan 2024 Form 3 Insider Report for ArriVent Biopharma, Inc. (AVBP)

Role
President of R&D, Director
Signature
/s/ James Kastenmayer, Attorney-in-Fact for Stuart Lutzker
Issuer symbol
AVBP
Transactions as of
25 Jan 2024
Net transactions value
$0
Form type
3
Filing time
25 Jan 2024, 20:39:12 UTC
Next filing
14 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AVBP Common Stock 147,744 25 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AVBP Stock Option (right to buy) 25 Jan 2024 Common Stock 65,746 $2.28 Direct F2, F3
holding AVBP Stock Option (right to buy) 25 Jan 2024 Common Stock 24,983 $2.28 Direct F3, F4
holding AVBP Stock Option (right to buy) 25 Jan 2024 Common Stock 42,735 $2.28 Direct F3, F4
holding AVBP Stock Option (right to buy) 25 Jan 2024 Common Stock 42,734 $3.65 Direct F3, F5
holding AVBP Stock Option (right to buy) 25 Jan 2024 Common Stock 49,309 $7.76 Direct F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the 15.21-for-1 reverse stock split of the Issuer's common stock effected on January 23, 2024 in connection with the Issuer's initial public offering.
F2 The shares underlying this option vested as to 25% on September 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
F3 Reflects the 15.21-for-1 reverse stock split of the Issuer's common stock effected on January 23, 2024 in connection with the Issuer's initial public offering, pursuant to which (i) the number of shares of common stock underlying the option was divided by 15.21 and (ii) the exercise price of the option was multiplied by 15.21.
F4 The shares underlying this option vested as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
F5 The shares underlying this option vest as to 25% on February 1, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
F6 The shares underlying this option vest as to 25% on January 1, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney